{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT02071862","nct_id":"NCT02071862","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02071862. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity","label":"CB-839","type":"EXPERIMENTAL"},{"description":"CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity","label":"Pac-CB","type":"EXPERIMENTAL"},{"description":"CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity","label":"CBE","type":"EXPERIMENTAL"},{"description":"CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity","label":"CB-Erl","type":"EXPERIMENTAL"},{"description":"CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity","label":"CBD","type":"EXPERIMENTAL"},{"description":"CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity","label":"CB-Cabo","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2019-03","type":"ACTUAL"},"conditions":["Solid Tumors","Triple-Negative Breast Cancer","Non Small Cell Lung Cancer","Renal Cell Carcinoma","Mesothelioma","Fumarate Hydratase (FH)-Deficient Tumors","Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)","Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors","Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations","Tumors Harboring Amplifications in the cMyc Gene"],"enrollment":{"count":210,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CB-839","otherNames":["Glutaminase Inhibitor"],"type":"DRUG"},{"name":"Pac-CB","otherNames":["combo CB-839 and Paclitaxel"],"type":"DRUG"},{"name":"CBE","otherNames":["combo CB-839 and everolimus"],"type":"DRUG"},{"name":"CB-Erl","otherNames":["combo CB-839 and erlotnib"],"type":"DRUG"},{"name":"CBD","otherNames":["combo CB-839 and docetaxel"],"type":"DRUG"},{"name":"CB-Cabo","otherNames":["combo CB-839 and cabozantinib"],"type":"DRUG"}],"last_update":"2022-07-20","lead_sponsor":"Calithera Biosciences, Inc","official_title":"Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2019-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Safety and tolerability of CB-839: Incidence of adverse events","timeFrame":"Every 21 days from study start until disease progression or unacceptable toxicity, assessed for an expected average of 6 months"}],"references":[],"start_date":{"date":"2014-02"},"study_type":"INTERVENTIONAL","title":"Study of the Glutaminase Inhibitor CB-839 in Solid Tumors","url":"https://clinicaltrials.gov/study/NCT02071862"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02071862"}